世界中医药

目的:探讨参芪扶正注射液在进展期胃癌化疗过程中对患者免疫功能的影响。方法:2012年6月至2014年6月选取100例胃癌患者为研究对象,根据随机数字表将患者分为治疗组及对照组各50例,对照组给予常规化疗治疗,治疗组在对照组基础上给予参芪扶正注射液进行治疗,对比分析疗效治疗效果。2组分别于治疗前后采用美国贝克曼公司提供的Beckm Epics流式细胞仪测定外周血CD3+、CD4+、CD8+、CD4+/CD8+细胞比率。结果:治疗组近期总有效率为82%高于对照组60%,差异有统计学意义(P<0.05)。治疗组不良反应率为40%,不良反应级别主要为I~II级,对照组不良反应率为64%,不良反应级别主要为II~III级,差异有统计学意义(P<0.05)。观察治疗后CD3+、CD4+、CD4+/CD8+水平显著高于对照组,而CD8+水平则低于对照组(P<0.05)。结论:参芪扶正注射液能有效提高胃癌患者免疫功能,改善患者生存质量。

English Summary:

To investigate the influence of Shenqifuzheng injection on immune function in the course of chemotherapy of advanced gastric cancer patients. Methods: A total of 100 cases of gastric cancer patients (selected from June 2012 to June 2014) were randomly divided into observation group (n=50) and control group (n=50). The control group was treated with conventional chemotherapy and the observation group was given conventional chemotherapy plus Shenqi Fuzheng Injection. Both before and after treatment, the levels of CD3+, CD4+, CD8+, CD4+ / CD8+ cell ratio in peripheral blood of the two groups patients were recorded by Beckm Epics flow cytometry instrument produced by American Beckman company. Results: Total effect rate of the observation group was 82%, higher than that of control group (60%), and the difference was statistically significant (P<0.05). Adverse reaction rate of the observation group was 40%, and the level was among I ~ II. In contrast, the adverse reaction rate of the control group was 64%, and the level was among II ~ III. This difference shows statistical significance (P<0.05). The levels of CD3+, CD4+, CD4+ / CD8+ of the observation group were higher than those of the control group, whereas CD8+ levels were lower (P<0.05). Conclusion: Shenqi Fuzheng injection can improve immune function in patients with gastric cancer and improve their quality of life.

查看全文查看/发表评论下载PDF阅读器